Literature DB >> 1958290

Modulation of T-cell function by gliomas.

T Roszman1, L Elliott, W Brooks.   

Abstract

Patients with primary intracranial tumors (gliomas) exhibit a profound decrease in immunity, the mechanism of which has, until recently, remained obscure. Here Thomas Roszman, Lucinda Elliott and William Brooks reveal that T cells obtained from these patients exhibit defects in interleukin 2 secretion and in expression of the high-affinity IL-2 receptor and they discuss the role played by immunosuppressive factors produced by gliomas in inducing these defects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958290     DOI: 10.1016/0167-5699(91)90068-5

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  51 in total

Review 1.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

Review 2.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

3.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Authors:  Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

4.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

Review 5.  Intramedullary nailing as a 'second hit' phenomenon in experimental research: lessons learned and future directions.

Authors:  Nikolaos G Lasanianos; Nikolaos K Kanakaris; Peter V Giannoudis
Journal:  Clin Orthop Relat Res       Date:  2009-12-10       Impact factor: 4.176

6.  Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.

Authors:  Afsar Rahbar; Madeleine Cederarv; Nina Wolmer-Solberg; Charlotte Tammik; Giuseppe Stragliotto; Inti Peredo; Olesja Fornara; Xinling Xu; Mensur Dzabic; Chato Taher; Petra Skarman; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

Review 7.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

8.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

9.  Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.

Authors:  M G Kaplitt; J G Tjuvajev; D A Leib; J Berk; K D Pettigrew; J B Posner; D W Pfaff; S D Rabkin; R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2.

Authors:  U Herrlinger; R Buchholz; P Jachimczak; M Schabet
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.